Streetbeat News

Products Services

VCNX

Vaccinex, Inc. (NASDAQ:VCNX) will present findings from two Phase 2 studies of its lead product, pepinemab, at the Society for Immunotherapy of Cancer's Annual Meeting. The studies show pepinemab's ability to induce the formation of lymphoid structures in tumors, improving outcomes to immune checkpoint inhibitors. In one study, pepinemab combined with Merck's KEYTRUDA doubled objective responses and progression free survival in patients with hard-to-treat tumors. Another study with Emory University showed pepinemab, combined with nivolumab and/or ipilimumab, prevented tumor recurrence for over 2 years in patients.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:13 pm

CHGG

Chegg Inc's Q3 financial results show a revenue of $157.9 million, beating estimates of $152.67 million, and an EPS of 18 cents, beating estimates of 17 cents. However, revenues were down 4% YoY, with subscription services revenues and subscribers also decreasing. The company has started rolling out its new AI-powered user experience. Q4 revenue is expected to be between $185 million and $187 million. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating for Chegg and lowered the price target from $13 to $9.

Portfolio Pulse from Adam Eckert

October 31, 2023 | 1:13 pm

HOWL

Werewolf Therapeutics (NASDAQ:HOWL) will present interim clinical results from its ongoing Phase 1/1b study of WTX-124 at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data will provide early insight into the safety and antitumor activity of WTX-124. The company will also present data supporting the potential of its PREDATOR platform and INDUKINE product candidates. A conference call and webcast to review the initial clinical results will be held on November 3, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:11 pm

MSI

Japan's Narita International Airport has enhanced its emergency communication system by adopting Motorola Solutions' broadband push-to-talk service. This move is expected to boost productivity and collaboration with emergency services.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:11 pm

SPRC

SciSparc has received notice of acceptance from the Australian patent office for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment. This has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:11 pm

CREX

Digital signage solutions provider Creative Realities, Inc. (NASDAQ:CREX) has partnered with coffee franchise The Human Bean to modernize customer experiences across its drive-thru locations. The partnership aims to optimize order interactions, enhance menu visibility, and streamline operations. The collaboration includes pre-order screens with limited-time offers and promotions, a three-screen lit menu board, and integration with The Human Bean's point-of-sale (POS) provider for real-time menu and pricing updates.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:10 pm

LYEL

Lyell Immunopharma, Inc. (NASDAQ:LYEL) is presenting new nonclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The presentations include data on LYL119, its second generation ROR1-targeted CAR T cell product candidate, and its Epi-R P2 manufacturing process designed to shorten tumor infiltrating lymphocyte (TIL) manufacturing. The company also highlighted its collaboration with Outpace to enhance solid tumor T cell therapies and its rejuvenation technology to generate more stem-like T cells.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:09 pm

CNTX

Context Therapeutics announced preclinical data showing a differentiated and active profile of its Claudin 6-targeted bispecific antibody CTIM-76. The drug exhibits dose-proportional tumor responses and safety in preclinical models. Benchmarking studies support CTIM-76's differentiated product profile. The IND filing for CTIM-76 is on track for late Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:08 pm

MLNK

MeridianLink, Inc. (NYSE:MLNK) has announced a new integration with Experian, providing lenders with real-time access to verified income and employment information. The integration of Experian Verify with MeridianLink Consumer and Mortgage Credit Link will provide customers with enhanced capabilities that deliver a seamless digital lending experience. This move is expected to reduce risk, accelerate conversion, save money, and maintain compliance with the Fair Credit Reporting Act.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:08 pm

SRPT

Sarepta Therapeutics announced that its EMBARK trial did not meet the primary endpoint, leading to a drop in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:08 pm